JP7586830B2 - 低用量の三重複合製剤 - Google Patents

低用量の三重複合製剤 Download PDF

Info

Publication number
JP7586830B2
JP7586830B2 JP2021556884A JP2021556884A JP7586830B2 JP 7586830 B2 JP7586830 B2 JP 7586830B2 JP 2021556884 A JP2021556884 A JP 2021556884A JP 2021556884 A JP2021556884 A JP 2021556884A JP 7586830 B2 JP7586830 B2 JP 7586830B2
Authority
JP
Japan
Prior art keywords
dose
minimum
inhibitor
diabetic therapeutic
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021556884A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022529208A5 (cg-RX-API-DMAC7.html
JP2022529208A (ja
Inventor
マクマホン,ステファン
ロジャース,アンソニー
Original Assignee
ザ ジョージ インスティテュート フォー グローバル ヘルス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ ジョージ インスティテュート フォー グローバル ヘルス filed Critical ザ ジョージ インスティテュート フォー グローバル ヘルス
Publication of JP2022529208A publication Critical patent/JP2022529208A/ja
Publication of JP2022529208A5 publication Critical patent/JP2022529208A5/ja
Application granted granted Critical
Publication of JP7586830B2 publication Critical patent/JP7586830B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2021556884A 2019-03-25 2020-03-25 低用量の三重複合製剤 Active JP7586830B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16/364,063 US11033544B2 (en) 2019-03-25 2019-03-25 Low-dose triple combination formulation
US16/364,063 2019-03-25
PCT/IB2020/000214 WO2020194052A1 (en) 2019-03-25 2020-03-25 Low-dose triple combination formulation

Publications (3)

Publication Number Publication Date
JP2022529208A JP2022529208A (ja) 2022-06-20
JP2022529208A5 JP2022529208A5 (cg-RX-API-DMAC7.html) 2023-04-05
JP7586830B2 true JP7586830B2 (ja) 2024-11-19

Family

ID=72606637

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021556884A Active JP7586830B2 (ja) 2019-03-25 2020-03-25 低用量の三重複合製剤

Country Status (11)

Country Link
US (5) US11033544B2 (cg-RX-API-DMAC7.html)
EP (1) EP3946344A4 (cg-RX-API-DMAC7.html)
JP (1) JP7586830B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220004027A (cg-RX-API-DMAC7.html)
CN (2) CN113924096A (cg-RX-API-DMAC7.html)
AU (2) AU2020247542A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021018994A2 (cg-RX-API-DMAC7.html)
CA (1) CA3134800A1 (cg-RX-API-DMAC7.html)
MX (2) MX2021011746A (cg-RX-API-DMAC7.html)
TW (2) TW202102209A (cg-RX-API-DMAC7.html)
WO (1) WO2020194052A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11033544B2 (en) * 2019-03-25 2021-06-15 The George Institute for Global Health Low-dose triple combination formulation
KR102853692B1 (ko) * 2021-07-08 2025-09-02 한미약품 주식회사 시타글립틴, 다파글리플로진 및 메트포르민을 포함하는 경구용 복합정제
EP4415723A4 (en) * 2021-10-12 2025-09-03 Unison Pharmaceuticals Pvt Ltd PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF SITAGLIPTIN AND EMPAGLIFLOZIN
TR2023001202A1 (tr) * 2023-02-02 2024-08-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Fi̇lm kapli empagliflozin ve metformin hi̇droklorür tabletleri̇
KR20260000968A (ko) * 2024-06-26 2026-01-05 주식회사 종근당 제2형 당뇨병 치료용 조성물, 조합물 및 병용 요법

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012523374A (ja) 2009-02-13 2012-10-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Sglt2阻害剤、dpp−iv阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
JP2017515908A (ja) 2014-05-16 2017-06-15 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag Sglt2インヒビター誘発性グルカゴン分泌の抑制方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200904405A (en) * 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
WO2016040462A2 (en) * 2014-09-09 2016-03-17 ARKAY Therapeutics, LLC Formulations and methods for treatment of metabolic syndrome
US11033544B2 (en) * 2019-03-25 2021-06-15 The George Institute for Global Health Low-dose triple combination formulation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012523374A (ja) 2009-02-13 2012-10-04 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Sglt2阻害剤、dpp−iv阻害剤、更に必要により抗糖尿病薬を含む医薬組成物及びその使用
JP2017515908A (ja) 2014-05-16 2017-06-15 アストラゼネカ・アクチエボラーグAstrazeneca Aktiebolag Sglt2インヒビター誘発性グルカゴン分泌の抑制方法

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
49th annual meeting of the european-association-for-the-study-of-diabetes(EASD),2013年,abstract No.938
Diabetes Care,2014年,Vol.37,pp.740-750
e022448,BMJ Open,2018年,Vol.8,pp.1-6
Int J Clin Pract,2012年,Vol.66, No.5,pp.465-476
Japanese ClinicalMedicine,2012年,Vol.3,pp.1-7
医療薬学,2013年,Vol.39, No.5,pp.309-321
糖尿病,Vol.55, Suppl.1,P.S-123

Also Published As

Publication number Publication date
BR112021018994A2 (pt) 2022-02-08
CN119607213A (zh) 2025-03-14
EP3946344A4 (en) 2022-12-28
WO2020194052A1 (en) 2020-10-01
US20220226317A1 (en) 2022-07-21
CN113924096A (zh) 2022-01-11
AU2025226705A1 (en) 2025-09-25
MX2024013504A (es) 2024-12-06
US20220226315A1 (en) 2022-07-21
US11033544B2 (en) 2021-06-15
JP2022529208A (ja) 2022-06-20
MX2021011746A (es) 2021-10-22
US20220226316A1 (en) 2022-07-21
US20210260056A1 (en) 2021-08-26
AU2020247542A1 (en) 2021-11-11
TW202545526A (zh) 2025-12-01
TW202102209A (zh) 2021-01-16
CA3134800A1 (en) 2020-10-01
KR20220004027A (ko) 2022-01-11
US20200306246A1 (en) 2020-10-01
EP3946344A1 (en) 2022-02-09

Similar Documents

Publication Publication Date Title
EP4125896B1 (en) Treatment of type 2 diabetes with 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl} piperidin-1-yl)methyl]-1-[(2s)-oxetan-2-ylmethyl]-1h-benzimidazole-6-carboxylic acid or a pharmaceutically salt thereof
AU2020247542A1 (en) Low-dose triple combination formulation
US20220184070A1 (en) Low-dose triple combination formulation
EP2419097B1 (en) Pharmaceutical composition comprising (1s)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-d-glucitol and metformin and uses thereof in the treatment of diabetes
CA2751834C (en) Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
KR102240240B1 (ko) 다파글리플로진 l-프롤린과 항당뇨병제를 포함하는 약제학적 복합 제제
JP6358515B2 (ja) Sglt2阻害薬と抗高血圧薬との組み合わせ
CN104349790A (zh) 用于治疗糖尿病的葡萄糖激酶活化剂组合物
KR102760956B1 (ko) 제미글립틴 및 다파글리플로진을 포함하는 경구용 복합제제, 및 이의 제조 방법
EP2329820B1 (en) Pharmaceutical composition for treating hypertension and metabolic syndrome and use thereof
HK40124034A (zh) 低剂量三联组合制剂
HK40067275A (en) Low-dose triple combination formulation
HK40067219A (en) Low-dose triple combination formulation
KR20250173974A (ko) 엠파글리플로진 및 텔미사르탄을 함유하는 대사이상 관련 지방성 간질환 예방 또는 치료용 약학적 조성물
KR20220140343A (ko) 에보글립틴 및 메트포르민을 포함하는 경구용 복합제제 및 그의 제조방법
JPWO2002028398A1 (ja) 糖尿病治療用組成物
HK1102422B (en) Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
HK1102405B (en) Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents
HK1102422A1 (en) Combinations comprising dipeptidylpeptidase-iv inhibitors and antidiabetic agents

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211210

RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20221216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221216

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240410

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240910

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241009

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20241107

R150 Certificate of patent or registration of utility model

Ref document number: 7586830

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150